Cargando…

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET

Detalles Bibliográficos
Autores principales:	Weiss, Ido D., Huff, Lyn M., Evbuomwan, Moses O., Xu, Xin, Dang, Hong Duc, Velez, Daniel S., Singh, Satya P., Zhang, Hongwei H., Gardina, Paul J., Lee, Jae-Ho, Lindenberg, Liza, Myers, Timothy G., Paik, Chang H., Schrump, David S., Pittaluga, Stefania, Choyke, Peter L., Fojo, Tito, Farber, Joshua M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195380/ https://www.ncbi.nlm.nih.gov/pubmed/30349656 http://dx.doi.org/10.18632/oncotarget.26214

Ejemplares similares

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2017)

Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape
por: Fojo, Tito, et al.
Publicado: (2020)

Plerixafor
por: Slater, Susan
Publicado: (2012)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
por: Sison, Edward Allan R., et al.
Publicado: (2014)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma
por: Chifu, Irina, et al.
Publicado: (2020)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow
por: Devi, Sapna, et al.
Publicado: (2013)

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor
por: Girbl, Tamara, et al.
Publicado: (2014)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4
por: Hersi, Hersi Mohamed, et al.
Publicado: (2018)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Waiting for ASCO to “Walk the Walk”
por: Fojo, Tito
Publicado: (2023)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

Long‐term outcomes in patients with advanced adrenocortical carcinoma after image‐guided locoregional ablation or embolization
por: Mauda‐Havakuk, Michal, et al.
Publicado: (2021)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A
por: Yeral, Mahmut, et al.
Publicado: (2018)

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
por: McDermott, David H., et al.
Publicado: (2023)

P2 3-year observation study of Plerixafor use in New Zealand
por: Swinn, Tim, et al.
Publicado: (2021)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Development and validation of a predictive model to guide the use of plerixafor in pediatric population
por: Sebastien, Bernard, et al.
Publicado: (2022)

BEZ235: When Promising Science Meets Clinical Reality
por: Pongas, Georgios, et al.
Publicado: (2016)

(64)Cu-Labeled Ubiquitin for PET Imaging of CXCR4 Expression in Mouse Breast Tumor
por: Li, Huiqiang, et al.
Publicado: (2019)

SUN-335 The Chemokine Receptor 4 (CXCR4) Plays an Important Role in Adrenocortical Carcinoma Cell Proliferation
por: Kitawaki, Yuko, et al.
Publicado: (2019)

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs
por: Hübel, Kai, et al.
Publicado: (2018)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

FRI199 Severe Hypertriglyceridemia And Acute Pancreatitis In A Patient With Adrenocortical Carcinoma (ACC) Taking Mitotane
por: Cortez, Briana Noel, et al.
Publicado: (2023)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Safety and biodistribution of (111)In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
por: Lindenberg, Liza, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7hcsduldljdshmb3upmotuqhui